Cargando…

Clinical progression of patients with COVID-19 in Shanghai, China

BACKGROUND: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19. METHODS: In this retrospective, single-center study, we in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jun, Qi, Tangkai, Liu, Li, Ling, Yun, Qian, Zhiping, Li, Tao, Li, Feng, Xu, Qingnian, Zhang, Yuyi, Xu, Shuibao, Song, Zhigang, Zeng, Yigang, Shen, Yinzhong, Shi, Yuxin, Zhu, Tongyu, Lu, Hongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102530/
https://www.ncbi.nlm.nih.gov/pubmed/32171869
http://dx.doi.org/10.1016/j.jinf.2020.03.004
_version_ 1783511846236454912
author Chen, Jun
Qi, Tangkai
Liu, Li
Ling, Yun
Qian, Zhiping
Li, Tao
Li, Feng
Xu, Qingnian
Zhang, Yuyi
Xu, Shuibao
Song, Zhigang
Zeng, Yigang
Shen, Yinzhong
Shi, Yuxin
Zhu, Tongyu
Lu, Hongzhou
author_facet Chen, Jun
Qi, Tangkai
Liu, Li
Ling, Yun
Qian, Zhiping
Li, Tao
Li, Feng
Xu, Qingnian
Zhang, Yuyi
Xu, Shuibao
Song, Zhigang
Zeng, Yigang
Shen, Yinzhong
Shi, Yuxin
Zhu, Tongyu
Lu, Hongzhou
author_sort Chen, Jun
collection PubMed
description BACKGROUND: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19. METHODS: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020. RESULTS: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2–7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12–20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8–11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10–12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission. CONCLUSIONS: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19.
format Online
Article
Text
id pubmed-7102530
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71025302020-03-31 Clinical progression of patients with COVID-19 in Shanghai, China Chen, Jun Qi, Tangkai Liu, Li Ling, Yun Qian, Zhiping Li, Tao Li, Feng Xu, Qingnian Zhang, Yuyi Xu, Shuibao Song, Zhigang Zeng, Yigang Shen, Yinzhong Shi, Yuxin Zhu, Tongyu Lu, Hongzhou J Infect Article BACKGROUND: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19. METHODS: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020. RESULTS: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2–7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12–20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8–11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10–12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission. CONCLUSIONS: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19. The British Infection Association. Published by Elsevier Ltd. 2020-05 2020-03-19 /pmc/articles/PMC7102530/ /pubmed/32171869 http://dx.doi.org/10.1016/j.jinf.2020.03.004 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chen, Jun
Qi, Tangkai
Liu, Li
Ling, Yun
Qian, Zhiping
Li, Tao
Li, Feng
Xu, Qingnian
Zhang, Yuyi
Xu, Shuibao
Song, Zhigang
Zeng, Yigang
Shen, Yinzhong
Shi, Yuxin
Zhu, Tongyu
Lu, Hongzhou
Clinical progression of patients with COVID-19 in Shanghai, China
title Clinical progression of patients with COVID-19 in Shanghai, China
title_full Clinical progression of patients with COVID-19 in Shanghai, China
title_fullStr Clinical progression of patients with COVID-19 in Shanghai, China
title_full_unstemmed Clinical progression of patients with COVID-19 in Shanghai, China
title_short Clinical progression of patients with COVID-19 in Shanghai, China
title_sort clinical progression of patients with covid-19 in shanghai, china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102530/
https://www.ncbi.nlm.nih.gov/pubmed/32171869
http://dx.doi.org/10.1016/j.jinf.2020.03.004
work_keys_str_mv AT chenjun clinicalprogressionofpatientswithcovid19inshanghaichina
AT qitangkai clinicalprogressionofpatientswithcovid19inshanghaichina
AT liuli clinicalprogressionofpatientswithcovid19inshanghaichina
AT lingyun clinicalprogressionofpatientswithcovid19inshanghaichina
AT qianzhiping clinicalprogressionofpatientswithcovid19inshanghaichina
AT litao clinicalprogressionofpatientswithcovid19inshanghaichina
AT lifeng clinicalprogressionofpatientswithcovid19inshanghaichina
AT xuqingnian clinicalprogressionofpatientswithcovid19inshanghaichina
AT zhangyuyi clinicalprogressionofpatientswithcovid19inshanghaichina
AT xushuibao clinicalprogressionofpatientswithcovid19inshanghaichina
AT songzhigang clinicalprogressionofpatientswithcovid19inshanghaichina
AT zengyigang clinicalprogressionofpatientswithcovid19inshanghaichina
AT shenyinzhong clinicalprogressionofpatientswithcovid19inshanghaichina
AT shiyuxin clinicalprogressionofpatientswithcovid19inshanghaichina
AT zhutongyu clinicalprogressionofpatientswithcovid19inshanghaichina
AT luhongzhou clinicalprogressionofpatientswithcovid19inshanghaichina